Secretome Therapeutics - About the company
Secretome Therapeutics is a series B company based in Dallas (United States), founded in 2018 by . It operates as a Developer of cell-based therapies for multiple diseases. Secretome Therapeutics has raised $20.4M in funding. The company has 208 active competitors, including 65 funded and 44 that have exited. Its top competitors include companies like AskBio, Calliditas Therapeutics and Mission Therapeutics.
Company Details
Developer of cell-based therapies for multiple diseases. It offers a lead product STM-21 to prevent the inflammatory toxicities of cancer treatment which include cisplatin-induced acute kidney injury. It also offers STM-01 a cellular therapy comprised of the neonatal MSCs for restoring cardiac function in a heart attack.
- Website
- Phone Number
- +1
Key Metrics
Founded Year
2018
Location
Dallas, United States
Stage
Series B
Total Funding
in 1 round
Latest Funding Round
Investors
Ranked
29th among
Similar Companies
AskBio &
Secretome Therapeutics's funding and investors
Secretome Therapeutics has raised a total funding of $20.4M over 1 round.
Secretome Therapeutics has 1 institutional investor - .
Here is the list of recent funding rounds of Secretome Therapeutics:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Nov 25, 2024 | $20.4M | Series B | 3555247 | 6119256 | - |
Access funding benchmarks and valuations. Sign up today!View details of Secretome Therapeutics's funding rounds and investors
Secretome Therapeutics's founders and board of directors
The founders of Secretome Therapeutics is . is the CEO of Secretome Therapeutics.
View details of Secretome Therapeutics's Founder profiles and Board Members
Access ÃØÃÜÑо¿Ëù on any website
Our Google Chrome extension lets you view company details while browsing their websites
Secretome Therapeutics's Competitors and alternates
Top competitors of Secretome Therapeutics include AskBio, Calliditas Therapeutics and Mission Therapeutics. Here is the list of Top 10 competitors of Secretome Therapeutics, ranked by ÃØÃÜÑо¿Ëù score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st |  AskBio 2001, Durham (United States), Acquired | Provider of gene and protein therapies to treat various diseases | $235M | TPG, Golden Valley CapitalÌý&²¹³¾±è;Ìý | 65/100 |
2nd | Calliditas Therapeutics 2004, Stockholm (Sweden), Public | Provider of small molecule based drug for inflammatory kidney disease | $44.8M | Athyrium Capital Management, Sofinnova PartnersÌý&²¹³¾±è;Ìý | 62/100 |
3rd | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response | $179M | 61/100 | |
4th |  Juvenescence 2017, Dublin (Ireland), Series B | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | $290M | Foresite Capital, Fastforward InnovationsÌý&²¹³¾±è;Ìý | 61/100 |
5th | Developer of gene therapies for the treatment of cardiovascular disease | $80.6M | EDBI, Kurma PartnersÌý&²¹³¾±è;Ìý | 57/100 | |
6th |  Unicycive 2016, San Francisco (United States), Public | Developer of small molecule therapies for the treatment of kidney diseases | $1.55M | Great Point Partners, Vivo CapitalÌý&²¹³¾±è;Ìý | 57/100 |
7th | Biotherapeutics derived from proprietary adult stem cell-based technologies | - | Hercules Capital, ³Õ±ð°ù³¾Ã¶²µ±ð²Ô²õ³¦±ô³Ü²úÌý&²¹³¾±è;Ìý | 57/100 | |
8th | Akebia Therapeutics 2007, Cincinnati (United States), Public | Developing therapeutics solutions to treat patients with kidney disease | $91M | Novartis Venture Fund, Novo HoldingsÌý&²¹³¾±è;Ìý | 55/100 |
9th | RoosterBio 2012, Frederick (United States), Series B | Developer of human mesenchymal stem cells and extracellular vesicles | $38.4M | HHS, Vanedge CapitalÌý&²¹³¾±è;Ìý | 55/100 |
10th | Developer of drugs for heart failure treatment | $36.5M | Novo Holdings, IndustrifondenÌý&²¹³¾±è;Ìý | 54/100 | |
29th |  2018, Dallas (United States), Series B | Developer of cell-based therapies for multiple diseases | $20.4M | 45/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Secretome Therapeutics's competitors? Click to see the top ones
Secretome Therapeutics's Investments and acquisitions
Secretome Therapeutics has made no investments or acquisitions yet.
Reports related to Secretome Therapeutics
Here is the latest report on Secretome Therapeutics's sector:
View
News related to Secretome Therapeutics
Media has covered Secretome Therapeutics for a total of 11 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
Business Wire•Apr 22, 2025•Secretome Therapeutics
•
Business Wire•Mar 25, 2025•Secretome Therapeutics
•
Business Wire•Mar 21, 2025•Secretome Therapeutics
•
•
•
Dallas Innovates•Dec 10, 2024•Secretome Therapeutics
•
BioWorld•Nov 26, 2024•Secretome Therapeutics
•
Business Wire•Nov 25, 2024•Secretome Therapeutics
•
Business Wire•Oct 28, 2024•Secretome Therapeutics
•
Dallas Innovates•Sep 18, 2024•Secretome Therapeutics,
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Secretome Therapeutics
Explore our recently published companies
- Reprogram Biosciences - San Diego based, 2025 founded, Seed company
- g-techsolutions - Unfunded company
- stopnobodymove - Unfunded company
- robinhorstmann - Unfunded company
- mwka - Singapore based, Unfunded company
- dihlazio - Funding Raised company
